Combining tests to use as a tool
Doctors already know that there are prognostic tests that can help to predict the outcome and rate of recurrence in this group of patients. However, now the combination of the IHC4 test (developed by scientists at the Breast Cancer Now Institute of Cancer Research in London) and the new immune score test could lead to better diagnostic capabilities than the previously used Oncotype DX test.
Katherine Woods, the Senior Research Communications Manager of Breast Cancer Now says that it is promising to have this new immune tool to aid in the prognostic tests that are currently available to cancer patients. Woods says that the combination of the immune tool with other diagnostic tools and tests could help to more accurately discover which women are at the highest risk of having their breast cancer return. Through the automatic analysis of the distribution of immune cells inside of a tumor, chemotherapy treatment could be more easily validated by doctors.